ADHD: Applying Practice Guidelines to Improve Patient Outcome and Executive Function

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 2014-2025

  Biederman, Joseph ^a   Safren, Steven A ^a   Seidman, Larry J ^a   Spencer, Thomas J ^a   Wilens, Timothy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; COCAINE; DESIPRAMINE; DOPAMINE; GUANFACINE; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; PLACEBO; PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; BRAIN REGION; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG TOLERABILITY; EUPHORIA; HUMAN; META ANALYSIS; MONOTHERAPY; NEUROBIOLOGY; OPTIMAL DRUG DOSE; PARENTAL BEHAVIOR; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RELAXATION TRAINING; REVIEW; SOCIAL ADAPTATION; SYSTEMATIC REVIEW; TIC;

EID: 33846011070     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1223     Document Type: Review

References (110)

1. Posner MI, Raichle ME. Images of Mind. New York, NY: Scientific American Library; 1994
2. Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA 2002;288:1740-1748
3. Doyle AE, Faraone SV, Seidman LJ, et al. Are endophenotypes based on measures of executive functions useful for molecular genetic studies of ADHD? J Child Psychol Psychiatry 2005;46:744-803
4. Valera EM, Faraone SV, Murrav KE, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2006: Epub ahead of print
5. Filipek PA, Semrud-Clikeman M, Steingard RD. et al. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology 1997;48:589-601
6. Sowell ER, Thompson PM, Welcome SE, et al. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 2003;362:1699-1707
7. Swanson J, Castellanos FX, Murias M, et al. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Cur Opin Neurobiol 1998;8:263-271
8. Valera EM, Faraone SV, Biederman J, et al. Functional neuroanatomy of working memory in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:439-447
9. Makris N, Biederman J, Valera EM, et al. Cortical thinning of the attention and executive function networks in adults with attention-deficit/ hyperactivity disorder. Cereb Cortex 2006; Epub ahead of print
10. Bush G, Frazier JA, Rauch SL, et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry 1999;45:1542-1552
11. Sonuga-Barke JE. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 2003;27:593-604
12. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006:Epub ahead of print
13. Morrison JR, Stewart MA. A family history of the hyperactive child syndrome. Biol Psychiatry 1971;3:189-195
14. Cantwell DP. Psychiatric illness in the families of hyperactive children. Arch Gen Psychiatry 1972;27:414-417
15. Biederman J, Faraone SV, Keenan K, et al. Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1990;29:526-533
16. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-248
17. Thapar A, Holmes J, Poulton K, et al. Genetic basis of attention deficit and hyperactivity. Br J Psychiatry 1999;174:105-111
18. Hudziak JJ, Derks EM, Althoff RR, et al. The genetic and environmental contributions to attention deficit hyperactivity disorder as measured by the Conners' Rating Scales-Revised. Am J Psychiatry 2005;162:1614-1620
19. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323
20. Gill M, Daly G, Heron S, et al. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 1997;2:311-313
21. Swanson JM, Sunohara GA, Kennedy JL, et al. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach. Mol Psychiatry 1998;3:38-41
22. Giros B, Jaber M, Jones S, et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-612
23. Cook EHJr, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56:993-998
24. Biederman J, Wilens TE, Mick E, et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998;44:269-273
25. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909-1918
26. Barkley RA, Guevremont DC, Anastopoulos AD, et al. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics 1993;92:212-218
27. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-540
28. Rounsaville BJ, Carrol KM, Onken LS. A stage model of behavioral therapies research: getting started and moving from stage I. Clin Psychol Sci Pract 2001;8:133-142
29. Chambless DL, Baker MJ, Baucom LE, et al. Update on empirically validated therapies, II. Clin Psychol 1998;51:3-16. Available at: http://home.comcast. net/~dave.combs/valther.pdf. Accessed Nov 3, 2006
30. Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006;26:17-31
31. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995;15:819-844
32. Gould RA, Buckminster S, Pollack MH, et al. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Prac 1997;4:291-306
33. Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacol 1998;136:205-216
34. Gould RA, Safren SA, Washington DO, et al. A meta-analytic review of cognitive-behavioral treatments. In: Heimberg RG, Turk CL, Mennin DS, eds. Generalized Anxiety Disorder: Advances in Research and Practice. New York, NY: Guilford Press; 2004:248-264
35. Otto MW, Penava SJ, Pollock RA, et al. Cognitive-behavioral and pharmacologic perspectives on the treatment of posttraumatic stress disorder. In: Pollack MH, Otto MW, Rosenbaum JF, eds. Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies. New York, NY: Guilford Press; 1996:219-260
36. Dobson KS. A meta-analysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 1989;57:414-419
37. Robinson LA, Berman JS, Neimeyer RA. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychol Bull 1990;108:30-49
38. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord 1986;10:67-75
39. Simons A, Murphy G, Levine J, et al. Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry 1986;43:43-48
40. McLean PD, Hakstian AR. Relative endurance of unipolar depression treatment effects: longitudinal follow-up. J Consult Clin Psychol 1990;58:482-488
41. Wilson GT, Pike KM. Eating Disorders. In: Barlow DH, ed. Clinical Handbook of Psychological Disorders: A Step-by-Step Treatment Manual. 3rd ed. New York, NY: Guilford Press; 2001:332-375
42. Whittal ML, Agras WS, Gould RA. Bulimia nervosa: a meta-analysis of psychosocial and pharmacological treatments. Behav Ther 1999;30:117-135
43. Keuthen NJ, Stein DJ, Christenson GA. Help for Hair Pullers: Understanding and Coping with Trichotillomania. Oakland, Calif: New Harbinger Publications; 2001
44. Dunn RL, Schwebel AI. Meta-analytic review of marital therapy outcome research. J Fam Psychol 1995;9:58-68
45. Wheeler JG, Christenson A, Jacobson NS. Couple distress. In: Barlow DH, ed. Clinical Handbook of Psychological Disorders: A Step-by-Step Treatment Manual. 3rd ed. New York, NY: Guilford Press; 2001:609-630
46. Bach AK, Wincze JP, Barlow DH. Sexual dysfunction. In: Barlow DH, ed. Clinical Handbook of Psychological Disorders: A Step-by-Step Treatment Manual. 3rd ed. New York, NY: Guilford Press; 2001:562-608
47. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002;5:189-202
48. Wilens TE, Biederman J, Spencer TJ. Pharmacotherapy of attention deficit hyperactivity disorder in adults. CNS Drugs 1998;9:347-356
49. Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 1998;59(supp 7):76-79
50. Safren SA, Sprich S, Chulvick S, et al. Psychosocial treatments for adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:349-360
51. Stevenson CS, Whitmont S, Bornholt L, et al. A cognitive remediation programme for adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2002;36:610-616
52. Stevenson CS, Stevenson RJ, Whitmont S. A self-directed psychosocial intervention with minimal therapist contact for adults with attention deficit hyperactivity disorder. Clin Psychol Psychother 2003;10:93-101
53. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005;43:831-842
54. National Institute of Mental Health. CGI (Clinical Global Impression) scale. Psychopharmacol Bull 1985;21:839-843
55. Safren SA, Perlman C, Sprich S, et al. Mastering Your Adult ADHD: A Cognitive-Behavioral Treatment Program, Therapist Guide. New York, NY: Oxford University; 2005
56. Safren SA, Sprich S, Perlman CA, et al. Mastering Your Adult ADHD: A Cognitive-Behavioral Treatment Program, Client Workbook. New York, NY: Oxford University; 2005
57. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980
58. Sonuga-Barke EJ. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry 2005;57:1231-1238
59. Sergeant JA, Geurts H, Oosteraan J. How specific is a deficit of executive functioning for attention-deficit/hyperactivity disorder? Behav Brain Res 2002;130:3-38
60. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
61. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997;121:65-94
62. Doyle AE, Biederman J, Seidman L, et al. Diagnostic efficiency of neuropsychological test scores for discriminating boys with and without attention deficit hyperactivity disorder. J Consult Clin Psychol 2000;68:477-488
63. Biederman J, Monuteaux MC, Doyle AE, et al. Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol 2004;72:757-766
64. Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperacliviiy disorder. Am J Psychiatry 2006;163:1730-1738
65. Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1263-1272
66. Pliszka SR, Giahn DC, Semrud-Clikeman M. et al. Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naïve or in long-term treatment. Am J Psychiatry 2006;163:1052-1060
67. Rubia K, Overmeyer S, Taylor E, et al. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry 1999;156:891-896
68. Seidman LJ, Valera EM, Makris N, et al. Dorsolateral prefrontal and anterior cingulate cortex volumetric abnormalities in adults with attention-deficit/hyperactivity disorder identified by magnetic resonance imaging. Biol Psychiatry 2006: Epub ahead of print
69. Seidman LJ, Biederman J, Monuteaux MC, et al. Impact of gender and age on executive functioning: do girls and boys with and without attention deficit hyperactivity disorder differ neuropsychologically in preteen and teenage years? Dev Neuropsychol 2005;27:79-105
70. Seidman LJ, Biederman J, Monuteaux MC, et al. Learning disabilities and executive dysfunction in boys with attention deficit hyperactivity disorder. Neuropsychology 2001;15:544-556
71. Seidman LJ, Biederman J, Valera EM, et al. Neuropsychological functioning in girls with attention-deficit/hyperactivity disorder with and without learning disabilities. Neuropsychology 2006;20:166-177
72. Seidman U, Biederman J, Weber W, et al. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44:260-268
73. Huang-Pollack CL, Nigg JT, Haiperin JM. Single dissociation findings of ADHD deficits in vigilance but not anterior or posterior attention systems. Neuropsychology 2006;20:420-429
74. Dimoska A, Johnstone SJ, Barry RJ, et al. Inhibitory motor control in children with attention-deficit/hyperactivity disorder: event-related potentials in the stop-signal paradigm. Biol Psychiatry 2003;54:1345-1354
75. Houghton S, Douglas G, West J, et al. Differential patterns of executive function in children with attention-deficit hyperactivity disorder according to gender and subtype. J Child Neurol 1999;14:801-805
76. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 2005;57:1336-1346
77. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-445
78. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001;21:RC121
79. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52:456-463
80. Gatley SJ, Volkow ND, Gifford AN, et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl) 1999;146:93-100
81. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 2003;27:615-621
82. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001;68:611-627
83. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-395
84. Kollins SH, Rush CR, Pazzaglia PJ, et al. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998;6:367-374
85. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-1044
86. Dulcan M, Dunne JE, Ayers W, et al. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolecent Psychiatry. J Am Acad Child Adolesc Psychiatry 1997;36 (suppl 10):85S-121S
87. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-Up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-769
88. Zametkin AJ, Ernst M. Problems in the management of attention-deficit/ hyperactivity disorder. N Engl J Med 1999;340:40-46
89. Pelham WE, Gnagy EM, Burrows-MacLean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:E105
90. Wilens TE, Gignac M. Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408-414
91. Williams RJ, Goodale LA, Shay-Fiddler MA, el al. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict 2004;13:381-389
92. Hall KM, Irwin MM, Bowman KA, et al. Illicit use of prescribed stimulant medication among college students. J Am Coll Health 2005;53:167-174
93. Rapport MD, DuPaul GJ, Stoner G, et al. Comparing classroom and clinic measures of attention deficit hyperactivity disorder: differential, idiosyncratic, and dose-response effects of methylphenidate. J Consult Clin Psychol 1986;54:334-341
94. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90
95. Gutgesell H, Atkins D, Barst R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999;99:979-982
96. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:919-927
97. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006;149:112-119
98. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimutant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 2004;61:2391-2399
99. Adler LA, Reingold LS, Morrill-MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep 2006;8:409-415
100. Christman AK, Fermo JD, Markowitz JA, et al. Atomoxetine. a novel treatment for attention-deficit/hyperactivity disorder. Pharmacotherapy 2004;24:1020-1036
101. Gibson AP, Bettinger TL, Patel NC, et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006;40:1134-1142
102. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or in combination with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005;44:15-924
103. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005;65:1941-1949
104. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with atterition-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study, Pediatrics 2005;116:777-784. Available at www.pediatrics.org/cgi/contenl/full/116/6/e777 Accessed Oct 10, 2006
105. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801
106. Donnelly CL, Reimherr FW, Young JL. Differential diagnosis of adult ADHD and neighboring disorders. CNS Spectrums 2006;11(suppl 11):1-14
107. Solhkhah R, Wilens TE, Daly J, et al. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005;15:777-786
108. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003;42:886-894
109. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1551-1559
110. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-1074